[{"orgOrder":0,"company":"J. Peter Rubin, MD","sponsor":"Synedgen | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"J. Peter Rubin, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dermal Hydrogel","sponsorNew":"J. Peter Rubin, MD \/ Synedgen | US Department of Defense","highestDevelopmentStatusID":"11","companyTruncated":"J. Peter Rubin, MD \/ Synedgen | US Department of Defense"},{"orgOrder":0,"company":"University of North Carolina, Chapel Hill","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of North Carolina, Chapel Hill","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"University of North Carolina, Chapel Hill \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina, Chapel Hill \/ Eli Lilly"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"||Integrin alpha-4\/beta-7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kingman Regional Medical Center","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Kingman Regional Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kingman Regional Medical Center \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Kingman Regional Medical Center \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"University of Utah","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"Vasopressin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intermountain Health \/ University of Utah","highestDevelopmentStatusID":"11","companyTruncated":"Intermountain Health \/ University of Utah"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"University of North Carolina, Chapel Hill","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of North Carolina, Chapel Hill","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of North Carolina, Chapel Hill \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina, Chapel Hill \/ Bausch Health"},{"orgOrder":0,"company":"Catholic University of Korea","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Catholic University of Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catholic University of Korea \/ Viatris","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea \/ Viatris"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University Health Network, Toronto \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Novo Nordisk"},{"orgOrder":0,"company":"Jeffrey Alan Klein","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Jeffrey Alan Klein","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jeffrey Alan Klein \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Jeffrey Alan Klein \/ Inapplicable"},{"orgOrder":0,"company":"CellTherX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Microsurfaced Skin Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"CellTherX","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellTherX \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"CellTherX \/ Inapplicable"},{"orgOrder":0,"company":"North Memorial Health Care","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"North Memorial Health Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North Memorial Health Care \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"North Memorial Health Care \/ Inapplicable"},{"orgOrder":0,"company":"Coalition for National Trauma Research","sponsor":"Cerus Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Pathogen-Reduced Plasma","moa":"Immune","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Coalition for National Trauma Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coalition for National Trauma Research \/ Cerus Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Coalition for National Trauma Research \/ Cerus Corporation"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamad Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Illinois, Chicago \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Northwestern University","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Northwestern University \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"University of New Mexico","sponsor":"La Jolla Pharmaceutical | National Center for Advancing Translational Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of New Mexico","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Mexico \/ La Jolla Pharmaceutical | National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of New Mexico \/ La Jolla Pharmaceutical | National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"University of New Mexico","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of New Mexico","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Mexico \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of New Mexico \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"First Affiliated Hospital of Wannan Medical College","sponsor":"Wuhu City Second People\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Shenfu","moa":"Immune","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"First Affiliated Hospital of Wannan Medical College","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"First Affiliated Hospital of Wannan Medical College \/ Wuhu City Second People\u2019s Hospital","highestDevelopmentStatusID":"11","companyTruncated":"First Affiliated Hospital of Wannan Medical College \/ Wuhu City Second People\u2019s Hospital"},{"orgOrder":0,"company":"St. Louis University","sponsor":"Next Science","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Surgx Wound Gel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"St. Louis University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"St. Louis University \/ Next Science","highestDevelopmentStatusID":"11","companyTruncated":"St. Louis University \/ Next Science"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, approved the treatment of severe burns.
Reset All
Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.
